Gateways to clinical trials

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 27, Issue 6, 2005, Pages 411-461

  Bayes M ^a   Rabasseda, X ^b   Prous, J R ^b  

^a PROUS SCIENCE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; ATAZANAVIR; BIMATOPROST; CONJUGATED ESTROGEN; EPLERENONE; ESTRADIOL; ESTRADIOL ACETATE; EZETIMIBE; FONDAPARINUX; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; IVABRADINE; LUMIRACOXIB; MORPHINE DERIVATIVE; NESIRITIDE; OXIPURINOL; PEGINTERFERON; PIMECROLIMUS; PRASTERONE; PREGABALIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROFECOXIB; ROSUVASTATIN; SIMVASTATIN; SITAXSENTAN; TRAVOPROST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB;

ADRENAL INSUFFICIENCY; ANGINA PECTORIS; AUTOIMMUNE DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DIABETIC NEUROPATHY; DRUG DOSE REGIMEN; DRUG ELUTING STENT; DRUG INHIBITION; DRUG RESEARCH; ERYTHEMA; FEBRILE NEUTROPENIA; GLAUCOMA; HEADACHE; HEPATITIS C; HOT FLUSH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPEREMIA; HYPERLIPIDEMIA; INTRAOCULAR HYPERTENSION; LYMPHOCYTIC INFILTRATION; META ANALYSIS; METABOLIC SYNDROME X; NEUTROPENIA; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PULMONARY HYPERTENSION; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

CLINICAL TRIALS; HUMANS;

EID: 25844468976     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (307)

1. Mix, T.-C.H. et al. Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 2005, 149(3): 408.
2. Oliva, E.N., Ronco, F., Danova, M., Rovati, B., Dimitrov, B.D., Vincelli, I., Alati, C., Nobile, F. Darbepoetin efficacy in myelodysplastic syndrome. Blood 2004, 104 (11, Part 2): Abst 4704.
3. Benjamin, R.J. et al. Transfusion of S-303 treated RBCs to treat acute anemia during or following cardiac surgery: Results of a phase III trial. Blood 2004, 104 (11, Part 1): Abst 381.
4. Hopkins, T.V. et al. Pegfilgastrim in autoimmune neutrophenia. Blood 2004, 104 (11, Part 2): Abst 3790.
5. Tzung, T.Y., Wu, J.C. Lymphocytic infiltration of Jessner successfully treated with pimecrolimus 1% cream: Report of a case. J Eur Acad Dermatol Venereol 2004, 18 (Suppl. 2): Abst FC07.8.
6. Benjamin, D.K. et al. Safety and pharmacokinetics of anidulafungin in pediatric patients with neutropenia. 44th Intersci Conf Antimicrob Agents Chemother (Oct 30, 2004, Washington, DC) 2004: Abst A-34.
7. Conlan, M.G. et al. Antibody formation to S-303-treated RBCs in the setting of chronic RBC transfusion. Blood 2004, 104 (11, Part 1): Abst 382.
8. Bradner, J. et al. Fondaparinux in the treatment of heparin-induced thrombocytopenia. Blood 2004, 104 (11, Part 1): Abst 1775.
9. Ruzyllo, W. et al. Antianginal and antiischaemic effects of the If current inhibitor ivabradine compared to amlodipine as monotherapies in patients with chronic stable angina. Randomised, controlled, double-blind trial. Eur Heart J 2004, 25 (Suppl.): Abst 878.
10. Moussa, I., Ellis, S.G., Moses, J.W. et al. The impact of culprit lesion calcification in patients undergoing paclitaxel-eluting stent implantation: A TAXUS-IV sub study. 54th Annu Sci Sess Am Coll Cardiol (March 6, 2005, Orlando) 2005: Abst 1123-29.
11. Barragan, P., Seabra-Gomes, R., Lotan, C. et al. Sirolimus-eluting stent and unprotected left main stenosis: The multi-center e-CYPHER registry. Circulation 2004, 110 (17, Suppl. 3): Abst 3011.
12. Romero, M., De Lezo, J.S., Medina, A. et al. Randomized drug-eluting stent comparison: Rapamycin versus paclitaxel in coronary lesions prone to restenosis. Circulation 2004, 110 (17, Suppl. 3): Abst 2625.
13. Windecker, S. A randomized comparison of a sirolimus- with a paclitaxel-eluting stent for coronary revascularization: The SIR-TAX trial. Circulation 2004, 110(17, Suppl. 3): Abst 2626.
14. Akhter, M.W., Singh, H., Bourji, N. et al. Effects of intravenous nesiritide on renal hemodynamics in patients with congestive heart failure. Circulation 2004, 110 (17, Suppl. 3): Abst 2589.
15. Yin, D.D., Levorsen, A.L., Alemao, E.A., Cook, J.R. Cost effectiveness of ezetimibe co-administration in CHD/CHD equivalent patients not at goal with current statin therapy in Norway. Eur Heart J 2004, 25 (Suppl.): Abst P1868.
16. Ferreira, E., Feres, F., Abizaid, A. et al. Is there any difference in neointimal hyperplasia between small and large vessels after sirolimus-eluting stent implantation? A 3D-intravascular ultrasound study. 54th Annu Sci Sess Am Coll Cardiol (March 6, 2005, Orlando) 2005: Abst 1123-20.
17. Anderson, J., Zannad, F., Solomon, H., Mukherjee, R., Patni, R., Pitt, B. Efficacy of eplerenone in Killip Class II-III post AMI patients: Results from EPHESUS. 54th Annu Sci Sess Am Coll Cardiol (March 6, 2005, Orlando) 2005: Abst 1147-233.
18. Grube, E., Silber, S., Hauptmann, K.E., Russell, M.E. 3-Year follow-up of TAXUS I: A randomized, controlled study with polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2004, 110 (17, Suppl. 3): Abst 2464.
19. Nikolsky, E., Kosinski, E., Kosinski, E. et al. Impact of body mass index on restenosis after bare-metal and drug-eluting stent implantation: Analysis from the TAXUS-IV trial. 54th Annu Sci Sess Am Coll Cardiol (March 6, 2005, Orlando) 2005: Abst 1123-27.
20. Airoldi, F., Colombo, A., Michev, I. et al. Sirolimus eluting stents implantation in bifurcational coronary artery lesions utilizing the 'crush' technique immediate and mid term outcome. 54th Annu Sci Sess Am Coll Cardiol (March 6, 2005, Orlando) 2005: Abst 801-3.
21. Pache, J., Dibra, A., Mehilli, J. et al. Restenosis after coronary placement of the drug-eluting Cypher stent versus the bare Bestent 2: A randomized, angiographic, and clinical trial. Circulation 2004, 110 (17, Suppl. 3): Abst 2465.
22. Cardiome reports oxypurinol clinical results. Cardiome Pharma Press Release 2005
23. Cohen, A.T. et al. Benefit of fondaparinux in medical patients: A subgroup analysis. Blood 2004, 104 (11, Part 2): Abst 4079.
24. Fiessinger, J.N. S 18886, a new specific TP-receptor antagonist, is safe and as effective as aspirin in inhibiting platelet aggregation in patients with peripheral arterial disease. Eur Heart J 2004, 25 (Suppl.): Abst P573.
25. Belhassen, L. The TP receptor antagonist S 18886 improves endothelial dysfunction on a long-term basis in atherosclerotic patients. Eur Heart J 2004, 25 (Suppl.): Abst P603.
26. Utian, W.H., Speroff, L., Ellman, H., Dart, C. Comparative controlled trial of a novel oral estrogen therapy (estradiol acetate) for relief of menopausal symptoms. 15th Annu Meet North Am Menopause Soc (Oct 6, 2004, Washington, DC) 2004: Abst P-99.
27. Sitbon, O. et al. The endothelin-receptor antagonist bosentan for the treatment of pulmonary arterial hypertension (PAH) associated with congenital heart defects (CHD). Eur Respir J 2004, 24 (Suppl. 48): Abst 4331.
28. Frost, A., Langleben, D., Barst, R. Efficacy of sitaxsentan, an endothelin-A receptor antagonist in PAH in traditional vs. expanded study populations. Eur Respir J 2004, 24 (Suppl. 48): Abst P763.
29. Iofina, E., Skurzewski, P., Radke, P. et al. Superior acute and follow-up results of sirolimus-eluting stents compared to vascular brachytherapy for in-stent restenosis. 54th Annu Sci Sess Am Coll Cardiol (March 6, 2005, Orlando) 2005: Abst 857-5.
30. Dhatariya, K. et al. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes 2005, 54(3): 765.
31. Chen, J. et al. Histopathology, duration, clinical significance, and mechanism of hyperemia with bimatoprost therapy. 15th Annu Meet Am Glaucoma Soc (March 3, 2005, Snowbird) 2005: Poster 7.
32. Camras, C.B., Toris, C.B., Zhan, G. et al. Effect of travoprost on diurnal and nocturnal aqueous humor dynamics in patients with ocular hypertension (OHT). 1st Joint Meet Am Acad Ophthalmol Eur Soc Ophthalmol (Oct 23, 2004, New Orleans) 2004: Abst PO060.
33. Maddala, Y., Cotoman, G., Lebovitz, P., Aggrawal, R. Use of infliximab, pegylated interferon and ribavirin in a patient with Crohn's disease and hepatitis C infection. Am J Gastroenterol 2004, 99 (10, Suppl.): Abst 809.
34. Fricke, J. et al. Lumiracoxib 400 mg provides a rapid onset of analgesia in a range of acute pain models. 24th Annu Sci Meet Am Pain Soc (March 30, 2005, Boston) 2005: Abst 720.
35. Desjardins, P. et al. TQ-1011 is superior to morphine and placebo in alleviating moderate to severe postsurgical pain. 24th Annu Sci Meet Am Pain Soc (March 30, 2005, Boston) 2005: Abst 728.
36. Serpell, M. et al. Sativex® in the treatment of pain of neurological origin or symptoms of multiple sclerosis: Interim analysis of a long-term, open label, safety and tolerability study. 24th Annu Sci Meet Am Pain Soc (March 30, 2005, Boston) 2005: Abst 722.
37. Young, C. et al. A randomised controlled trial of cannabis based medicinal extract in central neuropathic pain due to multiple sclerosis. 24th Annu Sci Meet Am Pain Soc (March 30, 2005, Boston) 2005: Abst 718.
38. Ximenes, A. et al. Valdecoxib demonstrates comparable efficacy to diclofenac in treatment of acute low back pain. 3rd World Congr World Inst Pain (Sept 21, 2004, Barcelona) 2004: Abst.
39. Ekman, E.F., Gimbel, J.S., Williams, H.T., Shapiro, D.Y., Verburg, K.M. Analgesic efficacy of valdecoxib 40 mg qd in managing acute pain following anterior cruciate ligament reconstruction. Annu Meet Am Soc Anesthesiol (ASA) (Oct 23, 2004, Las Vegas) 2004: Abst A-35.
40. Hanna, M.H. et al. Randomized, double-blind study of the analgesic efficacy of morphine-6-glucuronide versus morphine sulfate for postoperative pain in major surgery. Anesthesiology 2005, 102(4): 815.
41. Cantillon, M. et al. Safety, tolerability and efficacy of intraoperative ALGRX 4975 in a randomized, double-blind, placebo-controlled study of subjects undergoing bunionectomy. 24th Annu Sci Meet Am Pain Soc (March 30, 2005, Boston) 2005: Abst 762.
42. Jay, R.M., Hillstrom, H.J., Jacobs, E.L., Brown, M.T., Verburg, K.M. Analgesic efficacy of valdecoxib in the management of acute pain following bunionectomy. Annu Meet Am Soc Anesthesiol (ASA) (Oct 23, 2004, Las Vegas) 2004: Abst A-58.
43. Malone, D.C., Tran, T.T. Cost-efficacy analysis of peginterferon-alpha2b plus ribavirin compared to peginterferon-alpha2a plus ribavirin for treatment of chronic hepatitis C. Pharmacotherapy 2004, 24(10): Abst 245A.
44. Thaci, D., Paetzold, S., Kaufmann, R., Boehncke, W.H. Hepatitis C infection and treatment of psoriasis with alefacept. J Eur Acad Dermatol Venereol 2004, 18 (Suppl. 2): Abst P06.81.
45. Easterbrook, P., Green, S., Wilken, A. et al. Antiretroviral (ARV) therapy in special populations: Response to lopinavir/ritonavir (LPV/r), tenofovir (TDF), and emtricitabine (FTC) in ARV-naive patients by gender, ethnicity, and hepatitis co-infection status. 7th Int Congr Drug Ther HIV Infect (Nov 14, 2004, Glasgow) 2004: Abst P15.
46. Casale, T.B. et al. Omalizumab pretreatment prevents allergic reactions due to rush immunotherapy (RIT). 61st Annu Meet Am Acad Allergy Asthma Immunol (March 18, 2005, San Antonio) 2005: Abst 259.
47. Majmundar, A., Khan, D. Successful therapy with omalizumab for imported fire ant anaphylaxis. 61st Annu Meet Am Acad Allergy Asthma Immunol (March 18, 2005, San Antonio) 2005: Abst 151.
48. Kline, J.N. et al. Omalizumab plus rush immunotherapy (RIT) is more effective than RIT alone in preventing ragweed-induced seasonal allergic rhinitis (SAR) symptoms. 61st Annu Meet Am Acad Allergy Asthma Immunol (March 18, 2005, San Antonio) 2005: Abst 827.
49. Langley, R., Luebbe, J., Diez, A.G., McGeown, C. Pimecrolimus cream 1% provides effective long-term management of atopic dermatitis: Results of an extended naturalistic study. 63rd Annu Meet Am Acad Dermatol (Feb 18, 2005, New Orleans) 2005: Abst P724.
50. McKenna, S., Matheson, R., Gulliver, W., Abrams, B. Impact of pimecrolimus cream 1% on quality of life in atopic dermatitis: Results from the 6-month, naturalistic nobel study. 63rd Annu Meet Am Acad Dermatol (Feb 18, 2005, New Orleans) 2005: Abst P720.
51. Kaufmann, R., Bieber, T., Helgesen, A. et al. Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2004, 18 (Suppl. 2): Abst P07.85.
52. Spergel, J., Nurse, N., Taylor, P., ParneixSpake, A. Effect of topical pimecrolimus on intracutaneous skin testing. J Eur Acad Dermatol Venereol 2004, 18 (Suppl. 2): Abst P07.67.
53. Hofmann, H., Szczepanski, R., Pigatto, P. et al. Naturalistic study of long-term management in patients over 3 months of age with mild or moderate atopic dermatitis using pimecrolimus cream 1%. J Eur Acad Dermatol Venereol 2004, 18 (Suppl. 2): Abst P07.86.
54. Stevenson, D.E. et al. A single dose of pegfilgrastim (Neulasta™) is effective in mobilizing CD34+ stem cells in patients undergoing autologous stem cell transplant. Blood 2004, 104 (11, Part 2): Abst 5000.
55. Pourpak, Z., Aghamohammadi, A., Farhoudi, A. et al. The effect of intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency. 1st Int Congr Immunodefic Disord (Feb 28, 2005, Tehran) 2005: Abst F-10.
56. Braxton, C.C. et al. Treatment of critically injured burn patients with drotrecogin alfa: Experience with eleven burn intensive care unit patients. Crit Care Med 2004, 32 (12, Suppl.): Abst 524.
57. Noy, A. et al. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: From the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol 2005, 23(5): 990.
58. Morrissey, C.O., Slavin, M.A., O'Reilly, M.A., Daffy, J., Coyle, L. Caspofungin (CAS) as salvage therapy (Rx) for invasive aspergillosis (IA): Results of the Australian compassionate access program (CAP). 44th Intersci Conf Antimicrob Agents Chemother (Oct 30, 2004, Washington, DC) 2004: Abst M-670.
59. Lat, I. et al. An evaluation of underuse of drotrecogin alfa for the treatment of S. pneumoniae bacteremia and severe sepsis. Crit Care Med 2004, 32 (12, Suppl.): Abst 563.
60. De Almeida, H.L., Filho, U.L.O. Topical pimecrolimus is an effective treatment for balanitis circinata erosiva. J Eur Acad Dermatol Venereol 2004, 18 (Suppl. 2): Abst P03.65.
61. Dworkin, R. et al. Long-term treatment of neuropathic pain and fibromyalgia syndrome with pregabalin in treatment-refractory patients. 24th Annu Sci Meet Am Pain Soc (March 30, 2005, Boston) 2005: Abst 686.
62. Lai, C.L. et al. Interim report for a phase II, multi-centre, dose-escalating study of LB80380/ANA380 in hepatitis B patients with lamivudine-resistant YMDD mutant HBV. 40th Annu Meet Eur Assoc Study Liver (April 13, 2005, Paris) 2005: Abst 72.
63. Lau, D. et al. Safety, tolerablity, pharmacokinetics and pharmacodynamics of remofovir in chronic HBV patients in US and Canada following daily dosing for 28 days. 40th Annu Meet Eur Assoc Study Liver (April 13, 2005, Paris) 2005: Abst 74.
64. Afdhal, N. et al. Enhanced antiviral efficacy of valopicitabine (NM283) plus PEG-interferon in hepatitis C patients with HCV genotype-1 infection: Results of a phase IIA multicenter trial. 40th Annu Meet Eur Assoc Study Liver (April 13, 2005, Paris) 2005: Abst 93.
65. Moreno, A., Quereda, C., Garcia-Garzon, S. et al. Comparative study of HCV RNA kinetics and sustained virological response after peg-IFN-alpha-2b/RBV in HCV-mono-infected, HCV/HIV-co-infected and liver transplanted patients. 12th Conf Retroviruses Opportunistic Infect (Feb 22, 2005, Boston) 2005: Abst 923.
66. Miralles, G.D., DeMasi, R.A. Comparison of antiretroviral agents in treatment-experienced patients: Enfuvirtide demonstrates superior efficacy compared to other available agents. 7th Int Congr Drug Ther HIV Infect (Nov 14, 2004, Glasgow) 2004: Abst P11.
67. Tomaras, G., McFarland, E., Johnson, D. et al. Anti-HIV antibodies elicited by prime boost vaccination, vCP1452 + AIDSVAX B/B, in newborns of HIV-infected mothers. 12th Conf Retroviruses Opportunistic Infect (Feb 22, 2005, Boston) 2005: Abst 779.
68. McFarland, E., Johnson, D., Muresan, P. et al. Safety and cell-mediated immune responses to prime-boost immunization with ALVAC HIV vaccine and AIDSVAX B/B in newborns of HIV-infected mothers (PACTG 326). 12th Conf Retroviruses Opportunistic Infect (Feb 22, 2005, Boston) 2005: Abst 48.
69. Stoehr, A., Graefe, K., Plettenberg, A. Atazanavir use in the German early access program. 7th Int Congr Drug Ther HIV Infect (Nov 14, 2004, Glasgow) 2004: Abst P42.
70. Hamad, W., Taylor, J., Natha, M. et al. Clinical experience with ritonavir boosted atazanavir. 7th Int Congr Drug Ther HIV Infect (Nov 14, 2004, Glasgow) 2004: Abst P41.
71. Rottman, C., Dauer, B., Hentig, N.V., Kurowski, M., Stuermer, M., Staszewski, S. Atazanavir/ritonavir/saquinavir without any other antiretroviral drugs in protease inhibitor experienced patients with no reverse transcriptase inhibitor options: A 24 week cohort analysis. 7th Int Congr Drug Ther HIV Infect (Nov 14, 2004, Glasgow) 2004: Abst P21.
72. Rutstein, R., Samson, P., Aldrovandi, G. et al. Effect of atazanavir on serum cholesterol and triglyceride levels in HIV-infected infants, children, and adolescents: PACTG 1020A. 12th Conf Retroviruses Opportunistic Infect (Feb 22, 2005, Boston) 2005: Abst 774.
73. Benson, C.A., Campbell, T., MaWhinney, S. et al. A pilot open-label phase II trial of the safety and efficacy of a compact 3-drug antiretroviral treatment regimen for subjects with acute or recent primary HIV-1 injection. 12th Conf Retroviruses Opportunistic Infect (Feb 22, 2005, Boston) 2005: Abst 570.
74. Beatty, G., Lu, J., Hunt, P. et al. Randomized pilot study of immediate enfuvirtide-based therapy vs a treatment interruption followed by enfuvirtide-based therapy in highly treatment-experienced patients. 12th Conf Retroviruses Opportunistic Infect (Feb 22, 2005, Boston) 2005: Abst 581.
75. Xu, F., Tomkins, S., Yates, P. et al. Genotypic inhibitory quotient predicts response to fosamprenavir/ritonavir. 7th Int Congr Drug Ther HIV Infect (Nov 14, 2004, Glasgow) 2004: Abst P141.
76. Vigano, A., Giacomet, V., Beretta, S., Merlo, M., Figini, C., Mora, S. Switching stavudine to tenofovir and protease inhibitor to efavirenz results in a favorable clinical outcome in HIV-infected children. 12th Conf Retroviruses Opportunistic Infect (Feb 22, 2005, Boston) 2005: Abst 770.
77. Schols, D. et al. Multi-drug resistant HIV-1 is sensitive to inhibition by chemokine receptor antagonists. 12th Conf Retroviruses Opportunistic Infect (Feb 22, 2005, Boston) 2005: Abst 545.
78. Milinkovic, A., Lopez, S., Vidal, S. et al. A randomized open study comparing the effect of reducing stavudine dose vs switching to tenofovir on mitochondrial function, metabolic parameters, and subcutaneous fat in HIV-infected patients receiving antiretroviral therapy containing stavudine. 12th Conf Retroviruses Opportunistic Infect (Feb 22, 2005, Boston) 2005: Abst 857.
79. Gallant, J., Parish, M., Keruly, J., Moore, R. Decline in renal function associated with tenofovir DF compared with nucleoside reverse transcriptase inhibitor treatment. 12th Conf Retroviruses Opportunistic Infect (Feb 22, 2005, Boston) 2005: Abst 820.
80. Khanlou, H., Guyer, B., Farthing, C. Efficacy of tenofovir-DF as intensification of zidovudine/lamivudine/abacavir fixed dose combination in the treatment of HIV-positive patients. 7th Int Congr Drug Ther HIV Infect (Nov 14, 2004, Glasgow) 2004: Abst P16.
81. Jain, M., Comanor, L., White, C. et al. Hepatitis B genotype A is associated with response to lamivudine or tenofovir in HBV/HIV co-infected patients. 12th Conf Retroviruses Opportunistic Infect (Feb 22, 2005, Boston) 2005: Abst 934.
82. Alvarez, D., Moorehead, L., Ball, L., Sulkowski, M. Effect of zidovudine on anemia and epoetin-alpha use during pegylated interferon/ribavirin therapy for HCV in HIV-infected persons. 12th Conf Retroviruses Opportunistic Infect (Feb 22, 2005, Boston) 2005: Abst 927.
83. Opravil, M., Sasadeusz, J., Cooper, D. et al. Effect of baseline CD4 count on efficacy and safety of pegylated interferon-alpha-2a (Pegasys) plus ribavirin in HIV/HCV co-infection: The AIDS Pegasys Ribavirin International Co-infection Trial (APRICOT). 12th Conf Retroviruses Opportunistic Infect (Feb 22, 2005, Boston) 2005: Abst 926.
84. Abraham, S., Jones, A., Toutous-Trellu, L. et al. Linear darier disease with herpes zoster infection treated successfully by brivudine. J Eur Acad Dermatol Venereol 2004, 18 (Suppl. 2): Abst P01.2.
85. Sension, M., Grinsztejn, B., Molina, J. et al. AI424067: Improvement in lipid profiles after 12 weeks of switching to atazanavir from boosted or unboosted protease inhibitors in patients with no previous PI virologic failure and hyperlipidemia at baseline. 12th Conf Retroviruses Opportunistic Infect (Feb 22, 2005, Boston) 2005: Abst 858.
86. Ford, J., Boffito, M., Wildfire, A. et al. Effect of atazanavir on intracellular and plasma pharmacokinetics of saquinavir ad ritonavir administered once daily in HIV infected patients. 7th Int Congr Drug Ther HIV Infect (Nov 14, 2004, Glasgow) 2004: Abst PL6.3.
87. Nasta, P., Paraninfo, G., Patroni, A., Costarelli, S., Carosi, G. Virological and immunological outcome of stavudine (d4T) and tenofovir (TDF) combination as NRTI backbone in patients with high rate of timidynic analogue mutations (TAM). 7th Int Congr Drug Ther HIV Infect (Nov 14, 2004, Glasgow) 2004: Abst P33.
88. Ribera, E., Paradineiro, J., Sauleda, S. et al. Improvement of subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir: The LIPOTEST study. 12th Conf Retroviruses Opportunistic Infect (Feb 22, 2005, Boston) 2005: Abst 860.
89. Moyle, G., Sabin, C., Cartledge, J. et al. A 48-week, randomized, open-label comparative study of tenofovir DF vs abacavir as substitutes for a thymidine analog in persons with lipoatrophy and sustained virological suppression on HAART. 12th Conf Retroviruses Opportunistic Infect (Feb 22, 2005, Boston) 2005: Abst 44LB.
90. Bickel, M., Lutz, T., Zangos, S. et al. Effects of recombinant human growth hormone (r-hGH) on fat depletion and plasma lipids in HIV-1-infected patients with lipodystrophy-a randomized, open-label study. 12th Conf Retroviruses Opportunistic Infect (Feb 22, 2005, Boston) 2005: Abst 855.
91. Buchanan, P. et al. Bacteriological efficacy of 5-day therapy with telithromycin in acute maxillary sinusitis. Int J Antimicrob Agents 2005, 25(3): 237.
92. Zaas, A.K., Ashley, E.S.D., Alexander, B.D., Johnson, M.D., Perfect, J.R. Caspofungin for invasive candidiasis: Experience at DUMC 2001-2004. 44th Intersci Conf Antimicrob Agents Chemother (Oct 30, 2004, Washington, DC) 2004: Abst M-1015.
93. Constantinides, C. et al. Reducing antibiotic reliance in the management of recurrent urinary tract infections. AMMI Canada-CACMID Annual Conference (April 14, 2005, Ottawa) 2005: Abst N4.
94. Griesing, T. et al. Pregabalin has rapid onset of sustainable pain relief in a study of post-herpetic neuralgia. Neurology 2005, 64 (6, Suppl. 1): Abst P02.157.
95. Sharma, U. et al. Efficacy, safety, and tolerability of pregabalin treatment for neuropathic pain: Findings from 11 clinical trials. 24th Annu Sci Meet Am Pain Soc (March 30, 2005, Boston) 2005: Abst 682.
96. van Seventer, R. et al. Neuropathic pain and sleep intererence associated with postherpetic neuralgia: Twice-daily pregabalin provides significant relief. 3rd World Congr World Inst Pain (Sept 21, 2004, Barcelona) 2004: Abst.
97. Gehanno, P., Lacroix, J., Leroy, B., Nusrat, R. Bacteriologic eradication of antibiotic-resistant Streptococcus pneumoniae with telithromycin in pediatric acute otitis media. 44th Intersci Conf Antimicrob Agents Chemother (Oct 30, 2004, Washington, DC) 2004: Abst G-2077.
98. Kraft, M. et al. Successful use of drotrecogin alfa (activated) in a patient receiving extracoporeal membrane oxygenation. Crit Care Med 2004, 32 (12, Suppl.): Abst 663.
99. Dhainaut, J.-F. et al. Safety profile of drotrecogin alfa (activated) in severe sepsis patients from the INDEPTH Integrated Database. Crit Care Med 2004, 32 (12, Suppl.): Abst 615.
100. Fortun, J., Martin-Davila, P., Navas, E. et al. Linezolid in the management of multiresistant tuberculosis. 44th Intersci Conf Antimicrob Agents Chemother (Oct 30, 2004, Washington, DC) 2004: Abst L-921.
101. McGill, J.B., Williams, M.E., Degenhardt, T.P., Szabo, J.R., Schotzinger, R.J. A phase 2 clinical investigation pyridoxamine (Pyridorin) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR-205/207). 37th Annu Meet Am Soc Nephrol (ASN) (Oct 27, 2004, St. Louis) 2004: Abst SU-PO152.
102. Speedel announces breakthrough phase II data with SPP301 for treatment of diabetic nephropathy. Speedel Pharma Press Release 2005
103. Iyengar, S., Lu, Y., D'Souza, D.N., Waninger, A., Tran, P., Wernicke, J.F. Duloxetine at doses of 60 mg once daily and 60 mg twice daily is effective in treatment of diabetic neuropathic pain. Neuropsychopharmacology 2004, 29 (Suppl. 1): S147.
104. Wernicke, J. et al. Duloxetine at doses of 60 mg QD and 60 mg BID is effective in treatment of diabetic neuropathic pain (DNP). 7th Annu Meet Am Soc Exp NeuroTher (March 3, 2005, Washington, DC) 2005: Abst 5.
105. Flamel Technologies announces public release of phase IIa data on Basulin. Flamel Press Release 2005
106. Herold, K.C., Gitelman, S., Masharani, U. et al. Treatment with hOKT3g1(Ala-Ala) improves insulin responses and reduces insulin requirements in patients with new onset type 1 diabetes (TIDM). Clin Invest Med 2004, 27 (4, Suppl.): Abst M38.78.
107. DeFronzo, R., Ratner, R., Han, J., Kim, D., Fineman, M., Baron, A. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. 40th Annu Meet Eur Assoc Study Diabetes (Sept 5, 2004. Munich) 2004: Abst 775.
108. NicOx announces NCX 4016 more effective than aspirin at preventing platelet activation in diabetes in phase IIa study. NicOx Press Release 2005
109. Davies, G.M., Masana, L., Gagne, C., Gumbiner, B., Veltri, E. Lipid lowering response of patients switching from statin monotherapy to ezetimibe co-administered with simvastatin. 15th Int Symp Drugs Affect Lipid Metab (Oct 24, 2004, Venice) 2004: 124.
110. Stein, E.A. et al. Ezetimibe added to rosuvastatin for severely hypercholesterolemic patients: Effects on low-density lipoprotein cholesterol and C-reactive protein. 54th Annu Sci Sess Am Coll Cardiol (March 6, 2005, Orlando) 2005: Abst 1070-129.
111. Deedwania, P.C. et al. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol 2005, 95(3): 360.
112. Plesa, M. et al. Ezetimibe for hypercholesterolemia in patients after heart transplant. J Invest Med 2005, 53 (Suppl. 1): S145.
113. Capps, N.B. Lipid responses to ezetimibe in clinical practice. 15th Int Symp Drugs Affect Lipid Metab (Oct 24, 2004, Venice) 2004: 113.
114. Wernicke, J. et al. The safety of duloxetine in the long-term treatment of diabetic neuropathic pain. 7th Annu Meet Am Soc Exp NeuroTher (March 3, 2005, Washington, DC) 2005: Abst 6.
115. Dukes, E. et al. Pregabalin significantly improves the health-related quality of life of patients with diabetic peripheral neuropathy: Findings from six randomized clinical trials. 24th Annu Sci Meet Am Pain Soc (March 30, 2005, Boston) 2005: Abst 685.
116. Jensen, M.D. Rimonabant in the treatment of metabolic syndrome: Pooled data from the RIO-Lipids, RIO-Europe and RIO-North America studies. 1st Int Congr "Prediabetes" Metab Syndr (April 13, 2005, Berlin) 2005: Abst.
117. Mease, P. et al. Adalimumab in psoriatic arthritis: 24-week results of a phase III study. 63rd Annu Meet Am Acad Dermatol (Feb 18, 2005, New Orleans) 2005: Abst P6.
118. Isaacs, J.D., Clarke, A.M., Hazleman, B.L., Hale, G., Waldmann, H., Symmons, D.P.M. Survival of patients after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis. 68th Annu Sci Meet Am Coll Rheumatol (Oct 16, 2004, San Antonio) 2004: Abst 1876.
119. Schiff, M.H., Keystone, B.C., Gibofsky, A. et al. Efficacy of anakinra (Kineret) in patients with rheumatoid arthritis previously refractory to TNF antagonists. 68th Annu Sci Meet Am Coll Rheumatol (Oct 16, 2004, San Antonio) 2004: Abst 920.
120. Arnold, L., Lu, Y., Rosen, A.S., D'Souza, D.N., Iyengar, S., Wernicke, J.F. Duloxetine in the treatment of fibromyalgia in women results from two clinical trials. Neuropsychopharmacology 2004, 29 (Suppl. 1): S123.
121. Tahir, H. et al. Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology (Oxford) 2005, 44(4): 561.
122. Yaffe, K. et al. Lasofoxifene does not affect cognitive function in postmenopausal women: Results from two phase 3 randomized controlled clinical trials for osteoporosis prevention. Neurology 2005, 64 (6, Suppl. 1): Abst S15.003.
123. Cantillon, M. et al. Preliminary safety, tolerability and efficacy of ALGRX 4975 in osteoarthritis (OA) of the knee. 24th Annu Sci Meet Am Pain Soc (March 30, 2005, Boston) 2005: Abst 723.
124. Jarrett, S.J., McGonagle, D., Marzo-Ortega, H., Henry, J., Emery, P. Etoricoxib reduces the need for biologic therapy in ankylosing spondylitis (AS) but has no effect on magnetic resonance imaging: Results from an open study. 68th Annu Sci Meet Am Coll Rheumatol (Oct 16, 2004, San Antonio) 2004: Abst 1634.
125. Goss, G. et al. A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND. 122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 2005, 23(2): 147.
126. Sullivan, D., Lush, R., Mahany, J. et al. A phase 1 study of epothilone B analog BMS-247550 in combination with carboplatin in recurrent and/or refractory solid tumors. Eur J Cancer Suppl 2004, 2(8): Abst 536.
127. Faivre, S., Delbaldo, C., Pautier, P. et al. Ixabepilone, a novel tubulin interacting agent, given every other week in combination with irinotecan in patients with advanced malignancies: A phase I and pharmacokinetic study. Eur J Cancer Suppl 2004, 2(8): Abst 534.
128. Grem, J.L. et al. Phase I and pharmacologic study of 17-(allylamino)-17- demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005, 23(9): 1885.
129. Meza, L.A. et al. Pegfilgrastim (Neulasta®) and filgrastim (Neupogen®) use in patients receiving chemotherapy in oncology practices: Interim results of the Assessment of Current CSF Evaluation for Proper Therapy (ACCEPT) study. Blood 2004, 104 (11, Part 2): Abst 5309.
130. Willis, F. et al. Pegfilgrastim alone successfully mobilizes peripheral CD34+ cells in chemotherapy naive subjects with solid tumors: Initial results of a phase 1-2 study. Blood 2004, 104(11, Part 1): Abst 2687.5.
131. Lara, P.N.m Jr. et al. Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: A phase I California Cancer Consortium Trial. Anti-Cancer Drugs 2005, 16(3): 317.
132. Vogel, C.L. et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005, 23(6): 1178.
133. Mazzolini, G., Alfaro, C., Sangro, B. et al. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol 2005, 23(5): 999.
134. Mirtsching, B.C. et al. Cetuximab in refractory metastatic colorectal cancer: Analysis of efficacy and response by patient and disease variables. Gastrointest Cancers Symp (Jan 27, 2005, Hollywood, FL) 2005: Abst 205.
135. Oxford Biomedica announces encouraging results from three phase II trials of Trovax in patients with colorectal cancer. Oxford Biomedica Press Release 2005
136. Kocakova, I., Dimitri, V., Spelda, S., Kocak, I. Therapy of GIST by imatinib mesylate (Glivec)-a specific inhibitor of the c-kit receptor tyrosine kinase. 16th Int Congr Anti-Cancer Treat (Feb 1, 2005, Paris) 2005: 251.
137. Schwartz, J.D. et al. Bevacizumab in hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. Gastrointest Cancers Symp (Jan 27, 2005, Hollywood, FL) 2005: Abst 134.
138. pSivida Limited reports positive phase IIa trial results in liver cancer. BrachySil trial confirms safety and tumor regression in further patients. pSivida Press Release 2005
139. Ishikawa, A. et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2005, 11(5): 1910.
140. Camps, C. et al. Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. Ann Oncol 2005, 16(4): 597.
141. Silverman, L.R., Johnston, E., Chahinian, P., Mandeli, J., Molineux, G. Peripheral blood progenitor cells (PBPCs) are effectively mobilised by pegfilgrastim (Neulasta). 9th Congr Eur Hematol Assoc (June 10, 2004, Geneva) 2004: Abst 148.
142. Manas, A. et al. Bladder instillations of hyaluronic acid for the prevention of urinary tract infections in patient s with acute metastatic medullar compression. AMMI Canada-CACMID Annual Conference (April 14, 2005, Ottawa) 2005: Abst H5.
143. Gulley, J. et al. A phase II study of a PSA-TRICOM vaccine, and the role of GM-CSF, in patients (pts) with metastatic androgen insensitive prostate cancer (AIPC). Prostate Cancer Symp (Feb 17, 2005, Orlando) 2005: Abst 287.
144. Dark, G.G. et al. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: A trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2005, 23(9): 1859.
145. Sessa, C. et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005, 23(9): 1867.
146. Senzer, N. et al. Completion of dose escalation component of phase II study of TNFerade combined with chemoradiation in the treatment of locally advanced pancreatic cancer (LAPC). Gastrointest Cancers Symp (Jan 27, 2005, Hollywood, FL) 2005: Abst 128.
147. Ardana announces successful results in phase II trial of Teverelix in prostate cancer. Ardana Biosciences Press Release 2005
148. Amato, R.J. et al. Phase II study of CC-4047 in patients with metastatic hormone-refractory prostate cancer (HRPC). Prostate Cancer Symp (Feb 17, 2005, Orlando) 2005: Abst 252.
149. Lin, A.M., Fong, K., Weinberg, V. et al. A phase II trial of imatinib mesylate in prostate cancer patients (pts) with biochemical relapse (BCR) after definitive local therapy. Prostate Cancer Symp (Feb 17, 2005, Orlando) 2005: Abst 258.
150. Morris, M.J., Beekman, K.W., Kelly, W.K. et al. Phase II study of bortezomib for castrate metastatic prostate cancer (PC). Prostate Cancer Symp (Feb 17, 2005, Orlando) 2005: Abst 277.
151. Foley, P., Freeman, M., Siller, G. et al. MAL-PDT or placebo cream in nodular basal cell carcinoma: Results of an Australian double-blind randomised multicenter study. Int Skin Cancer Conf (July 22, 2004, Zurich) 2004: Abst P22.
152. Vignetti, M., Fazi, P., Meloni, G. et al. Imatinib in adult and elderly Ph ALL patients: Preliminary results of the GIMEMA prospective study LAL0201. 9th Congr Eur Hematol Assoc (June 10, 2004, Geneva) 2004: Abst 385.
153. Ranze, O. et al. Pegfilgrastim provides safe and rapid neutrophil support in patients with acute myeloid leukemia (AML) undergoing myelosuppressive chemotherapy. Blood 2004, 104 (11, Part 2): Abst 4511.
154. Dartigeas, C. et al. Efficacy and safety of alemtuzumab in patients with relapsed B-cell chronic lymphocytic leukemia after autologous stem cell transplantation. Blood 2004, 104 (11, Part 1): Abst 2509.
155. Ritgen, M. et al. Consolidation with alemtuzumab in first remission induces pronounced mrd reduction and clinical remissions - Update on a randomized phase III trial of the German CLL Study Group (GCLLSG). Blood 2004, 104 (11, Part 1): Abst 2506.
156. Byrd, J.C. et al. Sequential phase II studies of flavopiridol by 72-hour continuous infusion and 1-hour intravenous bolus for the treatment of relapsed B-cell chronic lymphocytic leukemia: Results from CALGB Study 19805. Blood 2004, 104 (11, Part 1): Abst 3485.
157. Elter, T. et al. FluCam-a new, 4-weekly combination of fludarabine and alemtuzumab for patients with relapsed chronic lymphocytic leukemia. Blood 2004, 104 (11, Part 1): Abst 2517.
158. Castro, J.E. et al. A phase I/II trial of Xcellerated T cells™ in patients with chronic lymphocytic leukemia. Blood 2004, 104 (11, Part 1): Abst 2508.
159. Li, J.-M. et al. Phase I clinical trial of Glivec in combination with tetra-arsenic tetra-sulfide in the treatment of CML patients in advanced phase. Blood 2004, 104 (11, Part 2): Abst 4653.
160. Soydan, E., Civriz, S., Beksac, M. et al. Imatinib only for molecular relapse is not sufficient to achieve a durable complete chimeric status and molecular remission after Allo HCT in CML. Annu Meet Am Soc Blood Marrow Transplant (Feb 10, 2005, Keystone) 2005: Abst 72.
161. van Besien, K.W. et al. Fludarabine melphalan and alemtuzumab (Campath) conditioning for pts with high risk myeloid malignancies. High cure rate for pts with low leukemia burden. Blood 2004, 104 (11, Part 1): Abst 2321.
162. Gibbs, S.D. et al. Prolonged severe pancytopenia and myelodysplastic features following alemtuzumab therapy in patients with cutaneous T-cell lymphomas. Blood 2004, 104 (11, Part 1): Abst 2645.
163. Beaugrand, M. et al. Treatment of advanced hepatocellular carcinoma (HCC) by seocalcitol (a Vit D analogue) : An international randomized double-blind placebo-controlled study in 747 patients. 40th Annu Meet Eur Assoc Study Liver (April 13, 2005, Paris) 2005: Abst 37.
164. Hong, S. et al. Pegylated recombinant human granulocyte colony stimulating factor (pegfilgrastim) reduces hematological toxicity in dose-adjusted (DA) R-EPOCH in the treatment of diffuse large B cell lymphoma. Blood 2004, 104 (11, Part 2): Abst 4631.
165. Herbrecht, R. et al. Preliminary phase II study results of BBR2778 in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma. Blood 2004, 104 (11, Part 1): Abst 2489.
166. Federico, M. et al. The MYOCAN Study. A phase II study of cyclophosphamide, oncovin, Myocet™, and prednisone plus rituximab (R-COMP) in the treatment of elderly patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL). Blood 2004, 104 (11, Part 2): Abst 4586.
167. Younes, A. et al. Long-term safety and efficacy of single administration of a fixed dose pegfilgrastim (Neulasta) in inducing neutrophil count recovery after ABVD chemotherapy in patients with Hodgkin lymphoma. Blood 2004, 104 (11, Part 2): Abst 4646.
168. Lemoli, R.M. et al. Phase II study of a single pegfilgrastim injection as adjunct to chemotherapy to mobilize stem cells into peripheral blood of resistant/relapsed lymphoma patients. Blood 2004, 104 (11, Part 1): Abst 2871.
169. Fayad, L. et al. Preliminary results of a phase I/II trial of BBR-2778(pixantrone) in combination with fludarabine, dexamethasone, and rituximab (FPD-R) in the treatment of patients with relapsed/refractory indolent non-Hodgkin's lymphoma (NHL). Blood 2004, 104 (11, Part 1): Abst 1324.
170. Kaminski, M.S. et al. Tositumomab and iodine I 131 tositumomab (the Bexxar® therapeutic regimen) produced ongoing, durable remissions of more than 5 years in 9 patients with non-Hodgkin's lymphoma (NHL) in a pivotal study of patients refractory to their last chemotherapy. Blood 2004, 104 (11, Part 1): Abst 2631.
171. Rodriguez, M.A., Winter, J.N. Treatment response to single agent sphingosomal vincristine in patients with relapsed and/or refractory diffuse aggressive non-Hodgkin's lymphoma (NHL): Subgroup analyses. Blood 2004, 104 (11, Part 1): Abst 2488.
172. Stiff, P. et al. AMD3100 combined with standard doses of G-CSF leads to rapid, consistent mobilization of hematopoietic progenitor cells in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma. Blood 2004, 104 (11, Part 1): Abst 2847.
173. Kim, Y. et al. TLR9 agonist immunomodulator treatment of cutaneous T-cell lymphoma (CTCL) with CPG7909. Blood 2004, 104 (11, Part 1): Abst 743.
174. Zinzani, P.L. et al. Phase II study of alemtuzumab treatment in patients with pretreated T-cell lymphoma. Blood 2004, 104 (11, Part 2): Abst 4605.
175. Papp-Vary, M. et al. Single dose per cycle pegfilgrastim successfully supports full dose CHOP-21 in patients with post-transplant lymphoproliferative disorders (PTLD). Blood 2004, 104 (11, Part 2): Abst 4591.
176. Dispenzieri, A. et al. The lack of clinical efficacy of flavopiridol in patients with relapsed refractory myeloma. Blood 2004, 104 (11, Part 1): Abst 3461.
177. Kroeger, N. et al. Comparison between anti-thymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch in melphalan/fludarabine dose-reduced conditioning followed by HLA-matched and mismatched unrelated stem cell transplantation in patients with multiple myeloma. Blood 2004, 104 (11, Part 1): Abst 980.
178. Berenson, J.R. et al. Bortezomib in combination with melphalan in the treatment of relapsed or refractory multiple myeloma: A phase I/III study. Haematologica 2005, 90 (Suppl. 1): Abst PO.728.
179. Mateos, M.V. et al. A phase I/II national, multi-center, open-label study of Velcade plus melphalan and prednisone (V-MP) in elderly untreated multiple myeloma patients. Haematologica 2005, 90 (Suppl. 1): Abst PO.726.
180. Popat, R. et al. Combination therapy of PS-341 (bortezomib), adriamycin and dexamethasone (PAD) for untreated patients with multiple myeloma. Haematologica 2005, 90 (Suppl. 1): Abst PO.732.
181. Jagannath, S. et al. A phase 2 study of bortezomib as first-line therapy in patients with multiple myeloma. Blood 2004, 104 (11, Part 1): Abst 333.
182. Jagannath, S. et al. Bortezomib therapy alone and in combination with dexamethasone for patients with previously untreated multiple myeloma. Haematologica 2005, 90 (Suppl. 1): Abst PO.725.
183. Richardson, P.G. et al. Bortezomib demonstrates superior efficacy compared with high-dose dexamethasone, with predictable toxicity. Haematologica 2005, 90 (Suppl. 1): Abst PO.720.
184. Sonneveld, P. et al. Bortezomib as first relapse is superior to high-dose dexamethasone and more effective than when given later in relapsed multiple myeloma. Haematologica 2005, 90 (Suppl. 1): Abst PO.721.
185. Cavenagh, J.D. et al. PAD combination therapy (PS-341/bortezomib, adriamycin and dexamethasone) for previously untreated patients with multiple myeloma. Blood 2004, 104 (11, Part 1): Abst 1478.
186. Richardson, P.G. et al. Phase II trial of single agent bortezomib (Velcade®) in patients with previously untreated multiple myeloma (MM). Blood 2004, 104 (11, Part 1): Abst 336.
187. Richardson, P.O., Barlogie, B., Berenson, J. et al. Factors predictive of clinical outcome with bortezomib (Velcade) in patients with relapsed, refractory multiple myeloma. 9th Congr Eur Hematol Assoc (June 10, 2004, Geneva) 2004: Abst 365a.
188. REVLIMID® pivotal phase III multiple myeloma trials both exceed pre-specified interim efficacy endpoint. Celgene Press Release 2005.
189. Weber, D.M. et al. A multicenter, randomized, parallel-group, double-blind, placebo-controlled study of lenalidomide plus dexamethasone versus dexamethasone alone in previously treated subjects with multiple myeloma. Haematologica 2005, 90 (Suppl. 1): Abst PO.738.
190. Richardson, P.G. et al. A multicenter, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide in subjects with relapsed and refractory multiple myeloma. Haematologica 2005, 90 (Suppl. 1): Abst PO.737.
191. Mohamad, A.H. et al. A phase I, multi-dose, dose escalation study of SGN-40(anti-HuCD40 monoclonal antibody) in patients with refractory or recurrent multiple myeloma. Haematologica 2005, 90 (Suppl. 1): Abst F11.01.
192. Uy, G.L., Fisher, N.M., Devine, S.M. et al. Bortezomib does not adversely affect stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Annu Meet Am Soc Blood Marrow Transplant (Feb 10, 2005, Keystone) 2005: Abst 228.
193. Olin, R.L., Luger, S.M., Porter, D.L. et al. Pegfilgrastim versus filgrastim to accelerate hematopoietic recovery after high dose melphalan and autologous hematopoietic stem cell transplant (ASCT) for multiple myeloma. Annu Meet Am Soc Blood Marrow Transplant (Feb 10, 2005, Keystone) 2005: Abst 257.
194. AustCancer vaccine adjuvant demonstrates enhanced immune response in prostate cancer patients. Australian Cancer Technology Press Release 2005
195. Blazar, B.R. et al. Palifermin (a rHuKGF molecule) is safe and well tolerated in patients (Pts) with hematologic malignancies (HM) undergoing high-dose chemoradiotherapy (HD-CRT) followed by allogeneic hematopoietic stem cell transplantation (HSCT). Annu Meet Am Soc Blood Marrow Transplant (Feb 10, 2005, Keystone) 2005: Abst 11.
196. Sica, S., Piccirillo, N., De Matteis, S. et al. Peg-filgrastim after high dose chemotherapy and autologous peripheral blood stem cell transplantation for hematological malignancies: A matched-pair analysis. Blood 2004, 104 (11, Part 2): Abst 5035.
197. Kasche, A., Luderschmidt, S., Ring, J., Hein, R. PDT-induced pain is reduced in patients treated with methyl aminolevulinate (MAL) compared to aminolevulinic acid (ALA). Int Skin Cancer Conf (July 22, 2004, Zurich) 2004: Abst FC13.
198. Faderl, S., Rai, K.R., Gribben, J. et al. Phase 2 study of three doses of single agent bortezomib in patients with fludarabine-refractory B-cell CLL. Blood 2004, 104 (11, Part 2): Abst 4841.
199. Voralia, M. et al. Alemtuzumab immunotherapy provides effective cytoreduction prior to allogeneic stem cell transplantation for refractory lymphoproliferative disorders. Annu Meet Am Soc Blood Marrow Transplant (Feb 10, 2005, Keystone) 2005: Abst 74.
200. Hunter, Z.R., Branagan, A.R., Treon, S.P. Campath-1H in Waldenstrom's macroglobulinemia. Blood 2004, 104 (11, Part 2): Abst 4924.
201. Kalla, R., Strupp, M., Dichgans, M., Freilinger, T., Glasauer, S., Brandt, T. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. J Neurol 2004, 251 (Suppl. 3): Abst P476.
202. Froestl, W., Gallagher, M., Jenkins, H. et al. SGS742: The first GABAB receptor antagonist in clinical trials. Biochem Pharmacol 2004, 68(8): 1479.
203. Berman, B. et al. Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia. Mov Disord 2005, 20(2): 233.
204. Biton, V. et al. Safety, tolerability and pharmacokinetics of intravenous lacosamide as replacement for oral lacosamide in subjects with partial seizures. Neurology 2005, 64 (6, Suppl. 1): Abst P02.148.
205. Ben-Menachem, E. et al. Efficacy and safety of adjunctive oral lacosamide for the treatment of partial onset seizures in patients with epilepsy. Neurology 2005, 64 (6, Suppl. 1): Abst P03.101.
206. Ishimoto, T., Chiba, S., Takasaki, H., Tabata, K., Ishimaru, Y., Tamura, Y. Successful use of perospirone hydrochloride hydrate in 19 epileptic patients with psychiatric disorders. 24th CINP Congr (June 20, 2004, Paris) 2004: Abst P02.543.
207. Siddall, P. et al. Pregabalin safely and efficaciously treats chronic central neuropathic pain after spinal cord injury. 24th Annu Sci Meet Am Pain Soc (March 30, 2005, Boston) 2005: Abst 665.
208. Rosenberg, R.P., Rubens, R., Niewoehner, J. Four studies of eszopiclone in non-elderly and elderly patients with chronic insomnia. Pharmacotherapy 2004, 24 (10): Abst 296.
209. Wessel, T.C. et al. Twelve months of nightly eszopiclone treatment in patients with chronic insomnia: Assessment of long-term efficacy and safety. Neurology 2005, 64 (6, Suppl. 1): Abst P01.059.
210. Rubens, R. et al. Efficacy of eszopiclone in the treatment of sleep maintenance insomnia. Neurology 2005, 64 (6, Suppl. 1): Abst P01.060.
211. Alderman, J., Mandema, J., Cox, E., Sikes, C. Eletriptan vs. sumatriptan for acute treatment of migraine pain: Meta-analysis of therapeutic benefits. 8th Congr Eur Fed Neurol Soc (Sept 4, 2004, Paris) 2004: Abst P2214.
212. Hettiarachchi, J., Sikes, C., Sun, W. Sustained response in the acute treatment of migraine: Results of placebo-controlled studies comparing electriptan with sumatriptan, zolmitriptan and naratriptan. 8th Congr Eur Fed Neurol Soc (Sept 4, 2004, Paris) 2004: Abst P2232.
213. Sikes, C., Sun, W., Hettiarachchi, J. Oral eletriptan vs. subcutaneous sumatriptan: An open-label crossover study of patient preference in the acute treatment of migraine. 8th Congr Eur Fed Neurol Soc (Sept 4, 2004, Paris) 2004: Abst P2221.
214. Schoenen, J. et al. Patient preference for eletriptan 80 mg versus subcutaneous sumatriptan 6 mg: Results of a crossover study in patients who have recently used subcutaneous sumatriptan. Eur J Neurol 2005, 12(2): 108.
215. Panitch, H. et al. A double-blind, placebo-controlled, multicenter study to assess the safety and efficacy of AVP-923(dextromethorphan/quinidine) in the treatment of pseudobulbar affect in patients with multiple sclerosis. Neurology 2005, 64 (6, Suppl. 1): Abst S46.001.
216. Schimrigk, S.K. et al. An open-label, prospective study of oral fumaric acid therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS). Neurology 2005, 64 (6, Suppl. 1): Abst S46.003.
217. Khoury, S.J. et al. A phase I trial of CTLA4Ig treatment in MS. Neurology 2005, 64 (6, Suppl. 1): Abst S46.004.
218. Russo, E.B. Sativex cannabis based medicine maintains improvements in sleep quality in patients with multiple sclerosis and neuropathic pain. Neurology 2005, 64 (6, Suppl. 1): Abst P01.061.
219. Nurmikko, T.J. et al. A multi-centre, double-blind, randomized, placebo-controlled trial of oro-mucosal cannabis-based medicine in the treatment of neuropathic pain characterized by allodynia. Neurology 2005, 64 (6, Suppl. 1): Abst P06.119.
220. Gustorff, B. et al. A pilot study of ralfinamide in the treatment of patients with neuropathic pain (NP). Neurology 2005, 64 (6, Suppl. 1): Abst P02.154.
221. Weiner, D.M., Vanover, K.E., Hacksell, U., Brann, M.R., Davis, R.E. The tolerability of ACP-103, a 5-HT2A receptor inverse agonist in Parkinson's disease patients. Mov Disord 2005, 20 (Suppl. 10): Abst P241.
222. Mark, M.H. Long-term efficacy of istradefylline in patients with advanced Parkinson's disease. Mov Disord 2005, 20 (Suppl. 10): Abst P310.
223. Berchou, R.C., Chen, J.J. Rasagiline, a novel, potent, second-generation, selective, irreversible inhibitor of monoamine oxidase-B (MAO-B), improves freezing of gait (FOG) in advanced Parkinson's disease (PD) patients receiving levodapa/carbidopa (LD/CD). Pharmacotherapy 2004, 24 (10): Abst 186.
224. Lew, M. et al. Long-term efficacy of rasagiline in Parkinson's disease. Neurology 2005, 64 (6, Suppl. 1): Abst S47.005.
225. Chen, J.J., Berchou, R.C. Rasagiline, a selective, sec and-generation, irreversible inhibitor of monoamine oxidase type-B, is effective in patients older and younger than 65 years of age with early-to-advanced Parkinson's disease (PD). Pharmacotherapy 2004, 24(10): Abst 183.
226. Watts, R.L. et al. Efficacy of the rotigotine transdermal patch in patients with early-stage, idiopathic Parkinson's disease. Results of a multicenter, multinational, randomized, double-blind, placebo-controlled trial. 8th Congr Eur Fed Neurol Soc (Sept 4, 2004, Paris) 2004: Abst.
227. Watts, R.L. et al. Treatment with rotigotine transdermal system may attenuate progression of disability in patients with early-stage Parkinson's disease. Neurology 2005, 64 (6, Suppl. 1): Abst P02.103.
228. Hu, H.-H. et al. A dose finding and safety study of a recombinant human plasminogen activator (HTUPA) in patients with acute ischemic stroke. Stroke 2004, 35(6): e288.
229. Pohl, R.B. et al. Efficacy of pregabalin in the treatment of generalized anxiety disorder: Double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 2005, 25(2): 151.
230. Harpin, V., Prasad, S., Zhang, S., Michelson, D. Atomoxetine in the long term prevention of relapse in ADHD. Arch Dis Child 2004, 89 (Suppl. 1): Abst P8.
231. Michelson, D. et al. Atomoxetine in the long-term prevention of relapse in ADHD. 12th Assoc Eur Psychiatr Congr (April 14, 2004, Geneva) 2004: Abst.
232. Adler, L.A. et al. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: An interim analysis. J Clin Psychiatry 2005, 66(3): 294.
233. Allen, A.J. et al. Atomoxetine treatment in children with attention-deficit/hyperactivity disorder and comorbid tic disorders. 12th Assoc Eur Psychiatr Congr (April 14, 2004, Geneva) 2004: Abst.
234. Allen, A.J., Kurlan, R.M., Linder, S.L. et al. Atomoxetine treatment in children with attention-deficit/hyperactivity disorder and comorbid tic disorders. Eur Neuropsychopharmacol 2004, 14 (Suppl. 3): Abst P.6.039.
235. Scott, K. et al. Aripiprazole in acute mania: Results from a second placebo-controlled study. 12th Assoc Eur Psychiatr Congr (April 14, 2004, Geneva) 2004: Abst.
236. Van Peborgh, P. et al. Aripiprazole versus placebo in the treatment of acute mania. 12th Assoc Eur Psychiatr Congr (April 14, 2004, Geneva) 2004: Abst.
237. Montgomery, S.A., Keller, M., Ball, W. et al. Peptide approaches in the treatment of major depression - lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant. Eur Neuropsychopharmacol 2004, 14 (Suppl. 3): Abst S.13.05.
238. Thase, M.E. et al. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol 2005, 25(2): 132.
239. Swindle, R., Jr., Mallinckrodt, C., Lu, Y., Watkin, J. Efficacy of duloxetine treatment: Analysis of pooled data from six placebo- and SSRI-controlled clinical trials. Pharmacotherapy 2004, 24(10): Abst 297E.
240. Kobak, K.A. et al. St. John's wort versus placebo in social phobia. Results from a placebo-controlled pilot study. J Clin Psychopharmacol 2005, 25(1): 51.
241. Kujawa, M., Stringfellow, J., Hardy, S. et al. Efficacy, safety, and tolerability of aripiprazole in patients with schizoaffective disorder. Schizophr Res 2004, 67 (1, Suppl. 1): Abst 305.
242. Kostic, D. et al. Short-term effect of aripiprazole in the symptoms of depression, anxiety, and hostility in schizophrenia. 12th Assoc Eur Psychiatr Congr (April 14, 2004, Geneva) 2004: Abst.
243. Octavio, I. et al. Broad effectiveness trial with aripiprazole. 12th Assoc Eur Psychiatr Congr (April 14, 2004, Geneva) 2004: Abst.
244. Stock, E., Archibald, D.G., Tourkodimitris, S. et al. Long-term effects of aripiprazole and haloperidol on affective symptoms of schizophrenia. Schizophr Res 2004, 67 (1, Suppl. 1): Abst 312.
245. Kane, J., Carson, W.H., Kujawa, M. et al. Aripiprazole in treatment-resistant schizophrenia: A 6-week double-blind comparison study versus perphenazine. Schizophr Res 2004, 67 (1, Suppl. 1): Abst 304.
246. Gismondi, R. et al. Aripiprazole for long-term maintenance treatment of schizophrenia. 12th Assoc Eur Psychiatr Congr (April 14, 2004, Geneva) 2004: Abst.
247. Archibald, D.G., Manos, G., Stock, E. et al. Effects of long-term aripiprazole therapy on the negative symptoms of schizophrenia. Schizophr Res 2004, 67 (1, Suppl. 1): Abst 302.
248. Clinical trial demonstrates improved sexual desire in women with low libido after treatment with VIVUS' testosterone spray. Vivus, Inc. Press Release 2005
249. Ghoniem, G.M. et al. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol 2005, 173(5): 1647.
250. Freemont, A.J., Denton, J., Paap, C. The effects of lanthanum carbonate and calcium carbonate on bone in patients with chronic kidney disease. Pharmacotherapy 2004, 24(10): Abst 180E.
251. Bitner, M. et al. Lumiracoxib 400 mg once daily provides predictable efficacy in primary dysmenorrhea. 24th Annu Sci Meet Am Pain Soc (March 30, 2005, Boston) 2005: Abst 719.
252. Palatin Technologies and King Pharmaceuticals report positive data from clinical trial evaluating co-administration of PT-141 and Viagra®. Palatin Technologies Press Release 2005
253. Hatzichristou, D. et al. Effect of tadalafil (Cialis™) on sexual timing behaviour patterns in men with erectile dysfunction: Integrated analysis of randomised, placebo-controlled trials. Eur Urol Suppl 2005, 4(3): Abst 541.
254. Mazer, N.A. Transdermal testosterone therapy for women with premature ovarian failure. Eur J Clin Invest 2005, 35 (Suppl. 2): Abst 201.
255. Roehrborn, C., O'Leary, M. Measurement of the effect of dutasteride on worry and embarrassment associated with lower urinary tract symptoms in men BPH: Use of novel instrument. Eur Urol Suppl 2005, 4(3): Abst 838.
256. Corren, J. et al. Omalizumab is well tolerated in adolescent/adult patients (equal to or more than 12 years) with moderate-to-severe persistent asthma. 61st Annu Meet Am Acad Allergy Asthma Immunol (March 18, 2005, San Antonio) 2005: Abst 301.
257. Chipps, B. et al. Omalizumab significantly improves quality of life in patients with severe persistent asthma. 61st Annu Meet Am Acad Allergy Asthma Immunol (March 18, 2005, San Antonio) 2005: Abst 19.
258. Berger, W. et al. Omalizumab significantly reduces asthma exacerbations in patients with severe persistent asthma: A pooled analysis. 61st Annu Meet Am Acad Allergy Asthma Immunol (March 18, 2005, San Antonio) 2005: Abst 299.
259. Korenblat, P. et al. Omalizumab add-on therapy significantly reduces asthma exacerbations in patients with inadequately controlled severe persistent asthma despite GINA 2002 step 4 therapy: INNOVATE. 61st Annu Meet Am Acad Allergy Asthma Immunol (March 18, 2005, San Antonio) 2005: Abst 306.
260. Maqbool, S. et al. Safety and efficacy of omalizumab in atopic dermatitis-a preliminary report. 61st Annu Meet Am Acad Allergy Asthma Immunol (March 18, 2005, San Antonio) 2005: Abst 423.
261. Cunha, P.R. An experience with pimecrolimus cream 1% in the treatment of rosacea. J Eur Acad Dermatol Venereol 2004, 18 (Suppl. 2): Abst P03.80.
262. Balasoiu, V., Mihai, D., Naumescu, E. Results of our clinical experience with pimecrolimus therapy. J Eur Acad Dermatol Venereol 2004, 18 (Suppl. 2): Abst P07.81.
263. Gutmane, R., Chigorevska, L., Azarjana, K., Petkevicha, A. Treatment of atopic dermatitis with pimecrolimus (Elidel 1% cream) in Latvia. J Eur Acad Dermatol Venereol 2004, 18 (Suppl. 2): Abst P07.74.
264. Langley, R. et al. Long-term safety and efficacy of adalimumab in the treatment of moderate to severe chronic plaque psoriasis. 63rd Annu Meet Am Acad Dermatol (Feb 18, 2005, New Orleans) 2005: Abst P8.
265. Gordon, K., Langley, R., Leonardi, C., Toth, D., Menter, A., Chen, D. Treatment of moderate to severe plaque psoriasis with 24 weeks of adalimumab. J Eur Acad Dermatol Venereol 2004, 18(Suppl. 2): Abst P06.40.
266. Sobera, J., Parrish, C., Elewski, B. Improvement in nail psoriasis with alefacept. J Am Acad Dermatol 2004, 50 (3, Suppl.): Abst P562.
267. Menter, A. et al. Long-term use of alefacept: Efficacy and off-treatment responses in patients who have received multiple courses of therapy. 63rd Annu Meet Am Acad Dermatol (Feb 18, 2005, New Orleans) 2005: Abst P7.
268. Anstey, A.V., Bibby, A.J. A pooled analysis of studies with a two-compound product (calcipotriol/betamethasone dipropionate) shows effective and rapid response in psoriasis vulgaris. J Eur Acad Dermatol Venereol 2004, 18 (Suppl. 2): Abst P06.94.
269. Bellini, M. Connection of 308 nm excimer laser and calcipotriol/ betamethasone diproprionate ointment in treating psoriasis. J Eur Acad Dermatol Venereol 2004, 18 (Suppl. 2): Abst FC04.3.
270. Tsogas, P. Evaluation of a new two-compound product (calcipotriol/ betamethasone dipropionate) for the treatment of psoriasis. J Eur Acad Dermatol Venereol 2004, 18 (Suppl. 2): Abst P06.99.
271. Thaci, D., Baur-Beger, S. Current experience with a new two-compound product (calcipotriol/betamethasone dipropionate) in the treatment of psoriasis: Results of an open cohort study. J Eur Acad Dermatol Venereol 2004, 18 (Suppl. 2): Abst P06.98.
272. Kragballe, K., Bibby, A. Repeated courses of a two-compound product (calcipotriol/betamethasone dipropionate) in psoriasis vulgaris. J Eur Acad Dermatol Venereol 2004, 18 (Suppl. 2): Abst P06.96.
273. Parslew, R., Traulsen, J. Efficacy and local safety of a calcipotriol/betamethasone dipropionate ointment in elderly patients with psoriasis vulgaris. Eur J Dermatol 2005, 15(1): 37.
274. Vakirlis, E., Kastanis, A., Lazaridou, E., Ioannides, D., Chrysomallis, F. Treatment of guttate psoriasis with a new two-compound product (calcipotriol/betamethasone dipropionate). J Eur Acad Dermatol Venereol 2004, 18 (Suppl. 2): Abst P06.100.
275. Gottlieb, A. et al. Maintenance of efficacy and safety with continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Final phase IIIb study results. 63rd Annu Meet Am Acad Dermatol (Feb 18, 2005, New Orleans) 2005: Abst P4.
276. Rotaru, M., Garlonta, V. Local treatment of pyoderma gangrenosum with 1% pimecrolimus. J Eur Acad Dermatol Venereol 2004, 18 (Suppl. 2): Abst P03.83.
277. Hoffman, H.M., Rosengren, S., Boyle, D.L. et al. Anakinra blocks cold-induced flares in familial cold autoinflammatory syndrome. 68th Annu Sci Meet Am Coll Rheumatol (Oct 16, 2004, San Antonio) 2004: Abst 1747.
278. Zempsky, W. et al. Randomized, double-blind, placebo-controlled study of ALGRX 3268: A topical lidocaine delivery system for topical anesthesia prior to venipuncture in children. 24th Annu Sci Meet Am Pain Soc (March 30, 2005, Boston) 2005: Abst 767.
279. Oda, Y., Nishikawa, K., Hase, I., Asada, A. The ultra-short-acting beta1-adrenoceptor antagonists esmolol and landiolol suppress the bispectral index response to tracheal intubation during sevoflurane anesthesia. Annu Meet Am Soc Anesthesiol (ASA) (Oct 23, 2004, Las Vegas) 2004: Abst A-305.
280. Gershlick, A.H., Guagliumi, G., Guyon, P. et al. Comparison of outcomes for sirolimus-eluting stent in the e-CYPHER registry with those from the randomized controlled trials (SIRIUS). 54th Annu Sci Sess Am Coll Cardiol (March 6, 2005, Orlando) 2005: Abst 807-5.
281. ZymoGenetics announces results of phase 2 clinical trials with recombinant human Thrombin. Company reaffirms plans to move forward with phase 3 clinical program. ZymoGenetics Press Release 2005
282. Sabzposh, S.W.A., Usmani, H., Sabzposh, N.A., Quadir, A., Bahl, N. Comparison of rofecoxib and valdecoxib for relief of pain after outpatient gynecological surgery. Annu Meet Am Soc Anesthesiol (ASA) (Oct 23, 2004, Las Vegas) 2004: Abst A-32.
283. Iyer, C. et al. Valdecoxib efficacy and safety with local anesthetic in continuous femoral catheter infusion in total knee replacement surgeries. Anesth Analg 2005, 100 (2, Suppl.): Abst S-429.
284. Iwasawa, K. et al. Effects of landiolol hydrochloride, ultra-short-acting, highly cardioselective beta-blocker, on hemodynamics in patients who underwent coronary artery bypass grafting. Anesth Analg 2005, 100 (2, Suppl.): Abst S-76.
285. Joshi, G.P. et al. Efficacy and safety of a single presurgical dose of IV parecoxib sodium followed by up to 7 days of oral valdecoxib for pain following laparoscopic cholecystectomy. 3rd World Congr World Inst Pain (Sept 21, 2004, Barcelona) 2004: Abst.
286. Kanaya, N. et al. The effect of landiolol on hemodynamic responses following endotracheal extubation. Anesth Analg 2005, 100 (2, Suppl.): Abst S-77.
287. Pavlakou, A. et al. Parecoxib sodium: Before or after surgery? 3rd World Congr World Inst Pain (Sept 21, 2004, Barcelona) 2004: Abst.
288. Magalhaes-Silverman, M., Carter, T., Hohl, R., Shamsuddin, H., Gingrich, R. Valganciclovir prophylaxis for the prevention of cytomegalovirus reactivation and disease in allogeneic stem cell transplant recipients. Annu Meet Am Soc Blood Marrow Transplant (Feb 10, 2005, Keystone) 2005: Abst 258.
289. Chwalisz, K. et al. The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Hum Reprod 2005, 20(4): 1090.
290. Edward, D. et al. Bimatoprost-induced periocular skin hyperpigmentation: A histopathological study. 15th Annu Meet Am Glaucoma Soc (March 3, 2005, Snowbird) 2005: Paper 15.
291. Perrin, Y., Nguyen, M.T., Rousso, P. et al. Pharmacokinetic and pharmacodynamic profile of icatibant. Clin Pharmacol Ther 2004, 75(2): Abst PII-16.
292. Garber, M., Burke, J., Farber, R., Jochelson, P., Campbell, B. A crossover comparison of middle of the night dosing with indiplon-IR, zolpidem, and zopiclone in healthy volunteers. 24th CINP Congr (June 20, 2004, Paris) 2004: Abst P02.548.
293. InKine announces positive phase 3 study results of next generation purgative product-INKP-102. InKine Press Release 2005
294. Ogden, L. Systemic exposure to lidocaine and tetracaine is low after application of a lidocaine 7% and tetracaine 7% peel in adults. 63rd Annu Meet Am Acad Dermatol (Feb 18, 2005, New Orleans) 2005: Abst P577.
295. Ma, J.D. et al. Effect of the anti-cytomegalovirus (CMV) drug maribavir (MB) on the activities of cytochrome P450(CYP) 1A2, 2C9, 2C19, 2D6, 3A, N-acetyltransferase-2(NAT-2), and xanthine oxidase (XO) as assessed by the cooperstown 5+1 drug cocktail. Clin Pharmacol Ther 2005, 77(2): Abst PI-43.
296. Panchal, S. et al. Safety and tolerability of alvimopan in healthy volunteers following opioid withdrawal. 24th Annu Sci Meet Am Pain Soc (March 30, 2005, Boston) 2005: Abst 730.
297. Neurocrine Biosciences announces positive phase I results with its orally active GnRH receptor antagonist. Neurocrine Biosciences Press Release 2005
298. Stoltz, R. et al. Pharmacokinetics, metabolism and excretion of intravenous [14C]-palonosetron in healthy human volunteers. Biopharm Drug Dispos 2004, 25(8): 329.
299. Hindmarch, I. et al. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep 2005, 28(2): 187.
300. Hirawat, S. et al. Phase 1 multiple-dose safety and PK study of PTC124
301. Ausma, J., Pierard-Franchimont, C., Borgers, M., Pierard, G. The activity of R126638, a new triazole antifungal, as assessed by corneofungimetry. 63rd Annu Meet Am Acad Dermatol (Feb 18, 2005, New Orleans) 2005: Abst P1831.
302. Abbas, R., Hijazi, Y., Renzetti, L.M., Tang, J.P., Rames, A., Welker, H. Safety, tolerability, and pharmacokinetics of R411, a dual alpha4/beta1-alpha4/ beta7 integrin antagonist, after oral administration of single-ascending doses in healthy male subjects. J Allergy Clin Immunol 2004, 113 (2, Suppl.): Abst 770.
303. Dicenzo, R., Predko, L., Chen, A. et al. The effects of quercetin on the plasma and intracellular concentrations (IC) of saquinavir (SQV). 44th Intersci Conf Antimicrob Agents Chemother (Oct 30, 2004, Washington, DC) 2004: Abst A-1489.
304. Galmiche, J.P. et al. A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers. Aliment Pharmacol Ther 2005, 21(5): 575.
305. Targeted Genetics announces preliminary safety data from phase I HIV vaccine trial. Targeted Genetics Corp. Press Release 2005
306. Pandya, K.M., Magliocco, M., Malaviya, R., Yao, M. The effects of topically applied constituents of green tea (caffeine or (-)-epigallocatechin: EGCG) on UV-induced increase in PS3 and apoptotic markers in the skin of human volunteers: A pilot study. J Am Acad Dermatol 2004, 50 (3, Suppl.): Abst P471.
307. Dowell, J.A. et al. Tolerability and pharmacokinetics (PK) of co-administered anidulafungin (ANID) and voriconazole (VORI). 44th Intersci Conf Antimicrob Agents Chemother (Oct 30, 2004, Washington, DC) 2004: Abst A-462.